SG11201408502XA - Method of purifying an antibody - Google Patents

Method of purifying an antibody

Info

Publication number
SG11201408502XA
SG11201408502XA SG11201408502XA SG11201408502XA SG11201408502XA SG 11201408502X A SG11201408502X A SG 11201408502XA SG 11201408502X A SG11201408502X A SG 11201408502XA SG 11201408502X A SG11201408502X A SG 11201408502XA SG 11201408502X A SG11201408502X A SG 11201408502XA
Authority
SG
Singapore
Prior art keywords
international
microweg
nijmegen
synthon
designated states
Prior art date
Application number
SG11201408502XA
Other languages
English (en)
Inventor
Bastiaan Pieter Arian Kokke
Van Everdina Josephina Wilhelmina Wijk-Basten
De Thomas Antonius Bernardus Beijer
Pérez Maria Marzá
Michel Hendrikus Maria Eppink
Original Assignee
Synthon Biopharmaceuticals Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthon Biopharmaceuticals Bv filed Critical Synthon Biopharmaceuticals Bv
Publication of SG11201408502XA publication Critical patent/SG11201408502XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Water Supply & Treatment (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
SG11201408502XA 2012-06-21 2012-06-21 Method of purifying an antibody SG11201408502XA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2012/062014 WO2013189544A1 (en) 2012-06-21 2012-06-21 Method of purifying an antibody

Publications (1)

Publication Number Publication Date
SG11201408502XA true SG11201408502XA (en) 2015-01-29

Family

ID=46321045

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201408502XA SG11201408502XA (en) 2012-06-21 2012-06-21 Method of purifying an antibody

Country Status (14)

Country Link
US (1) US9845338B2 (ko)
EP (1) EP2864346B1 (ko)
KR (1) KR101941742B1 (ko)
CN (1) CN104487448B (ko)
CY (1) CY1121394T1 (ko)
DK (1) DK2864346T3 (ko)
ES (1) ES2704487T3 (ko)
HR (1) HRP20190030T1 (ko)
HU (1) HUE043121T2 (ko)
LT (1) LT2864346T (ko)
PL (1) PL2864346T3 (ko)
PT (1) PT2864346T (ko)
SG (1) SG11201408502XA (ko)
WO (1) WO2013189544A1 (ko)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7032046B2 (ja) * 2016-01-22 2022-03-08 旭化成メディカル株式会社 生理活性物質の連続的な定流速精製方法
WO2017143286A1 (en) * 2016-02-19 2017-08-24 Wilfred Chen Functionalized nanoparticles for enhanced affinity precipitation of proteins
CN111902720A (zh) 2018-03-21 2020-11-06 沃特世科技公司 基于非抗体高亲和力的样品制备、吸附剂、装置和方法
EP3546475A1 (en) * 2018-03-27 2019-10-02 Sanofi Full flow-through process for purifying recombinant proteins
KR102337683B1 (ko) * 2018-09-21 2021-12-13 주식회사 녹십자 고효율 항-tfpi 항체 조성물
TW202112801A (zh) * 2019-06-05 2021-04-01 美商西雅圖遺傳學公司 純化遮蔽抗體之方法
CN114539351B (zh) * 2022-01-26 2023-03-03 上海健士拜生物科技有限公司 纳米抗体的纯化方法
CN114409787A (zh) * 2022-02-18 2022-04-29 南京英瀚斯生物科技有限公司 一种针对her3纳米抗体的分离纯化方法
WO2023249892A1 (en) * 2022-06-20 2023-12-28 Amgen Inc. Clearance of aggregates from uf/df pools in downstream antibody purification

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7452539B2 (en) * 2001-12-19 2008-11-18 Genentech, Inc. Stabilizing polypeptides which have been exposed to urea
UA87836C2 (ru) * 2004-02-27 2009-08-25 Октафарма Аг Способ получения очищенных, безопасных с вирусологической точки зрения препаратов антител
BRPI0513706A (pt) * 2004-07-20 2008-05-13 Symphogen As anticorpo policlonal recombinante anti-rhesus d e métodos de produção
KR20150006085A (ko) * 2006-04-05 2015-01-15 애브비 바이오테크놀로지 리미티드 항체 정제
AU2008343347A1 (en) * 2007-12-21 2009-07-09 Genentech, Inc. Crystallization of anti-CD20 antibodies
CN102257007A (zh) * 2008-10-20 2011-11-23 雅培制药有限公司 与il-18结合的抗体及其纯化方法
SG175142A1 (en) * 2009-04-27 2011-12-29 Immuron Ltd Anti-lps enriched immunoglobulin preparation for use in treatment and/or prophylaxis of a pathologic disorder
US8956614B2 (en) * 2009-06-15 2015-02-17 Vib Vzw BACE1 inhibitory antibodies
US9345661B2 (en) * 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
WO2011015920A2 (en) 2009-08-03 2011-02-10 Avesthagen Limited A highly efficient process of purification and production of recombinant trastuzumab
GB201012603D0 (en) * 2010-07-27 2010-09-08 Ucb Pharma Sa Protein purification
US20120238730A1 (en) * 2011-03-15 2012-09-20 Abbott Laboratories Integrated approach to the isolation and purification of antibodies

Also Published As

Publication number Publication date
PT2864346T (pt) 2018-12-12
CN104487448A (zh) 2015-04-01
WO2013189544A1 (en) 2013-12-27
US9845338B2 (en) 2017-12-19
HUE043121T2 (hu) 2019-08-28
CN104487448B (zh) 2020-04-24
CY1121394T1 (el) 2020-05-29
EP2864346A1 (en) 2015-04-29
ES2704487T3 (es) 2019-03-18
EP2864346B1 (en) 2018-10-17
LT2864346T (lt) 2019-01-25
US20160002289A1 (en) 2016-01-07
PL2864346T3 (pl) 2019-04-30
KR20150027807A (ko) 2015-03-12
DK2864346T3 (en) 2019-02-04
HRP20190030T1 (hr) 2019-02-22
KR101941742B1 (ko) 2019-01-23

Similar Documents

Publication Publication Date Title
SG11201408502XA (en) Method of purifying an antibody
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201803900UA (en) Process for preparing polyurea microcapsules with improved deposition
SG11201901700UA (en) Biaryl compounds useful as immunomodulators
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201804398XA (en) Method for producing rna molecule compositions
SG11201408037SA (en) Humanized anti-trka antibodies with amino acid substitutions
SG11201804510PA (en) Biparatopic polypeptides antagonizing wnt signaling in tumor cells
SG11201407774XA (en) Conversion of biomass
SG11201408224SA (en) Novel ruthenium complexes, their use in the metathesis reactions, and a process for carrying out the metathesis reaction
SG11201408303WA (en) Adhesive compositions of propylene-based and ethylene-based polymers
SG11201811336TA (en) Method for producing an electrode catalyst from a perovskite metal oxide
SG11201403106SA (en) Anti-phf-tau antibodies and their uses
SG11201407233RA (en) Ethylene oligomerization process
SG11201407579QA (en) Interleukin-2 fusion proteins and uses thereof
SG11201807827VA (en) Process for the preparation of pegylated drug-linkers and intermediates thereof
SG11201407800SA (en) Selective binding of biological targets to solid phase ureides
SG11201408536WA (en) METHOD FOR PRODUCING SOLUBLE FcR AS Fc-FUSION WITH INERT IMMUNOGLOBULIN Fc-REGION AND USES THEREOF
SG11201809830WA (en) Selective reduction of cysteine-engineered antibodies
SG11201803692PA (en) Anti-5t4 antibodies and antibody-drug conjugates
SG11201902531QA (en) Liquid pharmaceutical composition
SG11201408396QA (en) Improved resid hydrotreating catalyst containing titania
SG11201805191SA (en) Yeast cell
SG11201408641UA (en) Phenoxyethyl piperidine compounds
SG11201407934UA (en) Camsylate salt